Current strategy for staging and treatment: the BCLC update and future prospects [0.03%]
现行分期与治疗策略：BCLC更新及未来展望
Alejandro Forner,María E Reig,Carlos Rodriguez de Lope et al.
Alejandro Forner et al.
Staging and treatment indication are relevant topics in the management of patients with hepatocellular carcinoma (HCC) and for optimal results, they have to take into account liver function, tumor stage, and physical status. For any staging...
Modified RECIST (mRECIST) assessment for hepatocellular carcinoma [0.03%]
改良版实体瘤疗效评价标准(mRECIST)在肝细胞癌中的应用评估研究
Riccardo Lencioni,Josep M Llovet
Riccardo Lencioni
The endpoint in cancer research is overall survival. Nonetheless, other potential surrogate endpoints, such as response rate and time to progression, are currently used. Measurement of response rate in hepatocellular carcinoma (HCC) has bec...
Molecular classification and novel targets in hepatocellular carcinoma: recent advancements [0.03%]
肝细胞癌的分子分类和新靶点：最近的研究进展
Yujin Hoshida,Sara Toffanin,Anja Lachenmayer et al.
Yujin Hoshida et al.
Hepatocellular carcinoma (HCC) is one of most lethal cancers worldwide. Strategic decisions for the advancement of molecular therapies in this neoplasm require a clear understanding of its molecular classification. Studies indicate aberrant...
Jens U Marquardt,Snorri S Thorgeirsson
Jens U Marquardt
Increasing evidence suggests that many, perhaps all solid tumors contain a subset of cells that possess functional properties similar to the normal tissue stem cells, including self-renewal, unlimited proliferative capacity, and pluripotenc...
Pathology of early hepatocellular carcinoma: conventional and molecular diagnosis [0.03%]
早期肝细胞癌的病理学：常规与分子诊断
Tania Roskams,Masamichi Kojiro
Tania Roskams
Recently, an East-West consensus on the histopathologic criteria for the diagnosis of high-grade dysplastic nodules (HGDN) versus early hepatocellular carcinoma (HCC) was reached. Next to classical morphologic criteria such as nucleocytopla...
Morris Sherman
Morris Sherman
Hepatocellular carcinoma (HCC) is increasing in incidence in many countries, and is the most common cause of death in patients with cirrhosis. With regular surveillance, small early HCC lesions can be identified. An algorithm has been devel...
Jordi Bruix,Josep M Llovet
Jordi Bruix
Drug-induced steatohepatitis leading to cirrhosis: long-term toxicity of amiodarone use [0.03%]
由胺碘酮使用引起的药物性脂肪肝炎至肝硬化的长期毒性反应
Kaiser Raja,Swan N Thung,M Isabel Fiel et al.
Kaiser Raja et al.
Nonalcoholic steatosis/steatohepatitis is the most common cause for abnormal liver chemistries. Apart from metabolic syndrome, drugs may also lead to development of steatohepatitis that may, rarely, progress to cirrhosis and portal hyperten...
Mark W Russo,Martin Scobey,Herbert L Bonkovsky
Mark W Russo
The "statins," or hydroxymethylglutaryl coenzyme A (HMG-CoA)-reductase inhibitors, are a generally safe class of drugs that are widely used throughout the world and are rarely associated with severe hepatotoxicity. In this article, two case...
Ann K Daly,Chris P Day
Ann K Daly
Genetic studies on drug-induced liver injury (DILI) have proved challenging, both because of their rarity and their difficulty in replicating observed effects. However, significant progress has now been achieved by both candidate-gene and g...